Medicine

Michael Har-Noy is an Immunologist and Bioengineer with over 30 years of experience in cellular immunotherapy, having developed and clinically tested unique LAK, TIL and Th1 cell therapies for cancer and HIV/AIDS as well as methods for their manufacturing under GMP. He has attended an MD-PhD program at Rush University Medical School in Chicago specializing in Immunology and Bioengineering and performed Postdoctoral work at the University of Minnesota. He did a Clinical Research Fellowship in Immunology and AIDS at Harvard University Medical School where he was appointed as an Officer. He is currently affiliated with the Department of Bone Marrow Transplantation and Cancer Immunotherapy at the Hadassah-Hebrew University Medical Center in Jerusalem. He is also the Founder and CEO of Immunovative Therapies, Ltd. He has over 200 issued patents in the field of immunotherapy and is an expert in the design and development of process control algorithms for large-scale, high density cell culture bioreactors. His passion is to develop effective, minimally toxic cancer vaccines that can be economically mass produced and distributed so that they can be affordable to patients suffering from advanced cancer in economically disadvantaged regions.